2023年欧洲肿瘤内科学会（ESMO）年会将于10月20日-24日在西班牙马德里召开。ESMO大会涵盖基础研究、转化研究以及最新临床研究进展，将为临床实践、多学科讨论等提供广阔、卓越的学术平台。医脉通特整理了乳腺癌领域重磅研究，以飨读者。

口头报告-早期乳腺癌

Proffered Paper session - Breast cancer, early stage  

日期：2023年10月20日，星期五

时间：14:00 - 15:40

主席：Stephen R. Johnston (London, United Kingdom)，Sara M. Tolaney (Boston, United States of America)

地点：Bilbao Auditorium - NCC

01

摘要号：LBA17

标题：Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

报告人：Nadia Harbeck (Munich, Germany)

时间：14:00 - 14:10

02

摘要号：LBA18

标题：Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study

报告人：Peter Schmid (London, United Kingdom)

时间：14:10 - 14:20

03

摘要号：LBA19

标题：Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

报告人：Luca Gianni (Milan, Italy)

时间：14:20 - 14:30

04

摘要号：LBA20

标题：A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

报告人：Sherene Loi (Melbourne, Australia)

时间：14:55 - 15:05

05

摘要号：LBA21

标题：KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

报告人：Fatima Cardoso (Lisbon, Portugal)

时间：15:05 - 15:15

迷你口头报告-早期乳腺癌

Mini Oral session - Breast cancer, early stage  

日期：2023年10月23日，星期一

时间：16:30 - 18:00

主席：Ines V. Vaz Luis (Villejuif, Cedex, France) ，Carsten Denkert (Marburg, Germany)， Ava Kwong (Hong Kong, Hong Kong PRC)

地点：Bilbao Auditorium - NCC

01

摘要号：238MO

标题：Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011

报告人：Beatrice Fervers (Lyon, France)

时间：16:30 - 16:35

02

摘要号：LBA22

标题：Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: results from the DISCO randomized trial

报告人：Beatrice Fervers (Lyon, France)

时间：16:35 - 16:40

03

摘要号：239MO

标题：Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

报告人：陈海珠（中国，广州）

时间：16:40 - 16:45

04

摘要号：240MO

标题：Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)

报告人：Matthew P. Goetz (Rochester, United States of America)

时间：17:00 - 17:05

05

摘要号：LBA23

标题：Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)

报告人：Aditya Bardia (Boston, United States of America)

时间：17:05 - 17:10

06

摘要号：241MO

标题：Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020

报告人：Irma Fredriksson (Stockholm, Sweden)

时间：17:10 - 17:15

07

摘要号：242MO

标题：Association of tumor-infiltrating lymphocytes (TILs) with Recurrence Score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC) - a translational analysis of four prospective multicentric studies.

报告人：Federica Miglietta (Padova, Italy)

时间：17:15 - 17:20

08

摘要号：LBA24

标题：Multiparametric prognostic score in early HR+/HER2- breast cancer: impact of Recurrence Score, clinical-pathological factors, gene mutations and histology

报告人：Oleg Gluz (Mönchengladbach, Germany)

时间：17:20 - 17:25

09

摘要号：243MO

标题：Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial

报告人：Henry M. Kuerer (Houston, United States of America)

时间：17:40 - 17:45

10

摘要号：244MO

标题：A Phase II Trial Targeting Disseminated Dormant Tumor Cells with Hydroxychloroquine, Everolimus or the Combination to Prevent Recurrent Breast Cancer (“CLEVER”)

报告人：Angela DeMichele (Philadelphia, United States of America)

时间：17:45 - 17:50

口头报告-转移性乳腺癌

Proffered Paper session - Breast cancer, metastatic

日期：2023年10月21日，星期六

时间：10:15 - 11:35

主席：Hervé Bonnefoi (Bordeaux, France)， Janice Wing-Hang Tsang (Hong Kong, Hong Kong PRC)

地点：Barcelona Auditorium - Hall 9

01

摘要号：381O

标题：First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors

报告人：张剑（中国，上海）

时间：10:15 - 10:25

02

摘要号：376O

标题：Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study

报告人：Shanu Modi (New York, United States of America)

时间：10:25 - 10:35

03

摘要号：377O

标题：A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

报告人：Sara A. Hurvitz (Santa Monica, United States of America)

时间：10:55 - 11:05

04

摘要号：378O

标题：Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) – first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool (MOATT) versus local routine patient coaching (LC).

报告人：Manfred K. Welslau (Aschaffenburg, Germany)

时间：11:05 - 11:15

迷你口头报告-转移性乳腺癌

Mini Oral session - Breast cancer, metastatic  

日期：2023年10月22日，星期日

时间：08:30 - 09:55

主席：Barbara Pistilli (Villejuif, Cedex, France)， Christoph Thomssen (Halle, Germany)， Hervé Bonnefoi (Bordeaux, France)

地点：Bilbao Auditorium - NCC

01

摘要号：379MO

标题：Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

报告人：Peter Schmid (London, United Kingdom)

时间：08:30 - 08:35

02

摘要号：380MO

标题：SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial

报告人：殷咏梅（中国，南京）

时间：08:35 - 08:40

03

摘要号：382MO

标题：Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer.

报告人：Nancy U. Lin (Boston, United States of America)

时间：08:55 - 09:00

04

摘要号：383MO

标题：Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study

报告人：Komal Jhaveri (New York, United States of America)

时间：09:00 - 09:05

05

摘要号：384MO

标题：Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

报告人：John Robertson (Nottingham, United Kingdom)

时间：09:05 - 09:10

06

摘要号：385MO

标题：A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

报告人：杜益群（中国，上海）

时间：09:25 - 09:30

07

摘要号：386MO

标题：Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial

报告人：Philippe G. Aftimos (Anderlecht, Belgium)

时间：09:30 - 09:35

08

摘要号：387MO

标题：First Results of the SOLTI-1903 HOPE's Patient-Centric Molecular Screening Program in Advanced Breast Cancer

报告人：Tomás Pascual (Barcelona, Spain)

时间：09:35 - 09:40

备注：排名不分先后，按照摘要号进行

如有遗漏或任何问题，请给我们留言~